Publication details

Exprese miR-195, miR-196b, miR-181c, miR-21 a metylační status MGMT promotoru koreluje s klinickou odpovědí u pacientů s multiformním glioblastomem.

Investor logo
Title in English MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients.
Authors

ŠÁNA Jiří HANKEOVÁ Simona LAKOMÝ Radek LŽIČAŘOVÁ Eva KŘEN Leoš FADRUS Pavel SMRČKA Martin VYZULA Rostislav SLABÝ Ondřej

Year of publication 2011
Type Conference abstract
Citation
Description lioblastoma multiforme (GBM) is the most frequently occurring primary malignant brain tumor; patients with GBM often have a very poor prognosis and differing responses to treatment. Therefore, it is very important to find new biomarkers that can predict clinical outcomes and help in treatment decisions. MicroRNAs are small, non-coding RNAs that function as post-transcriptional regulators of gene expression and play a key role in the pathogenesis of GBM. In a group of 38 patients with primary GBM, we analyzed the expression of eight microRNAs (miR-21, miR-128a, miR-181c, miR-195, miR-196a, miR-196b, miR-221, and miR-222). In addition, we examined the methylation status of O-6-methylguanine-DNA methyltransferase (MGMT) promoter by high-resolution melting analysis, as this has been shown to be a predictive marker in GBM.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info